Arrowhead Expands Board

Pasadena-based Arrowhead Research, the developer of nanomedicines, announced this morning that it has appointed Michael S. Perry, Hon BSc, DVM, Ph.D., to its board of directors. Perry is a venture partner at Bay City Capital, a life sciences investment fund, and also serves as President and Chief Medical Officerof Poniard Pharmaceuticals. Perry has also served at VIA Pharmaceuticals, Extropy Pharmaceuticals, Pharsight, SyStemix, Genetic Therapty, Baxter BIoScience, Novartis PHarma, and Syntex.